In Experimental hematology & oncology
Since U.S. President Barack Obama announced the Precision Medicine Initiative in his New Year's State of the Union address in 2015, the establishment of a precision medicine system has been emphasized worldwide, particularly in the field of oncology. With the advent of next-generation sequencers specifically, genome analysis technology has made remarkable progress, and there are active efforts to apply genome information to diagnosis and treatment. Generally, in the process of feeding back the results of next-generation sequencing analysis to patients, a molecular tumor board (MTB), consisting of experts in clinical oncology, genetic medicine, etc., is established to discuss the results. On the other hand, an MTB currently involves a large amount of work, with humans searching through vast databases and literature, selecting the best drug candidates, and manually confirming the status of available clinical trials. In addition, as personalized medicine advances, the burden on MTB members is expected to increase in the future. Under these circumstances, introducing cutting-edge artificial intelligence (AI) technology and information and communication technology to MTBs while reducing the burden on MTB members and building a platform that enables more accurate and personalized medical care would be of great benefit to patients. In this review, we introduced the latest status of elemental technologies that have potential for AI utilization in MTB, and discussed issues that may arise in the future as we progress with AI implementation.
Hamamoto Ryuji, Koyama Takafumi, Kouno Nobuji, Yasuda Tomohiro, Yui Shuntaro, Sudo Kazuki, Hirata Makoto, Sunami Kuniko, Kubo Takashi, Takasawa Ken, Takahashi Satoshi, Machino Hidenori, Kobayashi Kazuma, Asada Ken, Komatsu Masaaki, Kaneko Syuzo, Yatabe Yasushi, Yamamoto Noboru
2022-Oct-31
Artificial intelligence, Molecular tumor board, Natural language processing, Next-generation sequencing, Precision medicine
